Protein C zymogen in severe sepsis: a double-blinded, placebo-controlled, randomized study.

Pappalardo F, Crivellari M, Di Prima AL, Agracheva N, Celinska-Spodar M, Lembo R, Taddeo D, Landoni G, Zangrillo A.
Intensive Care Med. 2016 Jun 25. http://www.ncbi.nlm.nih.gov/pubmed/27344436

Purpura fulminans in sepsis

Betrosian AP, Berlet T, Agarwal B.
Am J Med Sci 2006; 332: 339-345 http://www.ncbi.nlm.nih.gov/pubmed/17170624

Purpura fulminans: recognition, diagnosis and management

Chalmers E, Cooper P, Forman K, Grimley C, Khair K, Minford A, Morgan M, Mumford AD
Arch Dis Child 2011; 96: 1066-1071 http://www.ncbi.nlm.nih.gov/pubmed/21233082

Acquired purpura fulminans

Francis R
Semin Thromb Hemostasis 1990; 16: 310-325 http://www.ncbi.nlm.nih.gov/pubmed/21233082

Acute infectious purpura fulminans: pathogenesis and medical management

Darmstadt GL
Pediat Dermatol 1998; 15: 169-183 http://www.ncbi.nlm.nih.gov/pubmed/9655311

Proposed classification and pathologic mechanisms of purpura fulminans and skin necrosis

Adcock DM, Brozna J, Marlar RA
Semin Thromb Hemostasis 1990; 16: 333-340 http://www.ncbi.nlm.nih.gov/pubmed/2281322

Diagnosis and management of neonatal purpura fulminans

Price VE, Ledingham DL, Krümpel A, Chan AK Semin Fetal Neonatal Med 2011; 16: 318-322
http://www.ncbi.nlm.nih.gov/pubmed/21839696

Coagulopathy of sepsis

Dempfle C-E
Thromb Haemost 2004; 91: 213-224 http://www.ncbi.nlm.nih.gov/pubmed/14961146

Veränderungen der Hämostase bei Sepsis: disseminierte intravasale Gerinnung, Verbrauchskoagulopathie und sepsisassoziierte Purpura fulminans

Dempfle CE
In: Sepsis und MODS, eds. K Werdan, H-P Schuster, U Muüller-Werdan; Springer, Heidelberg 2005 http://link.springer.com/chapter/10.1007%2F3-540-26587-2_19#

Do new strategies in meningococcemia produce better outcomes?

Leclerc F, Leteurtre S, Cremer R, Fourier C, Sadik A
Crit Care Med 2000; 28 (Suppl): S60-S63 http://www.ncbi.nlm.nih.gov/pubmed/11007200

An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans- associated meningococcemia

White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP
Blood 2000; 96: 3719-3724 http://www.ncbi.nlm.nih.gov/pubmed/11090052

Protein C substitution in sepsis-associated purpura fulminans

Rintala E, Kauppila M, Seppälä OP, Voipio-Pulkki LM, Pettilaä V, Rasi V, Kotilainen P
Crit Care Med 2000; 28: 2373-2378 http://www.ncbi.nlm.nih.gov/pubmed/10921567

Treatment of adult patients with sepsis- induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin)

Schellongowski P, Bauer E, Holzinger U, Staudinger T, Frass M, Laczika K, Locker GJ, Quehenberger P, Rabitsch W, Schenk P, Knoöbl P
Vox Sanguinis 2006; 90: 294-301 http://www.ncbi.nlm.nih.gov/pubmed/16635072

Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blind, placebo-controlle, dose-finding study

de Kleijn ED, de Groot R, Hack E, Mulder PGH, Engl W, Moritz B, Joosten KFM, Hazelzet JA
Crit Care Med 2003; 31: 1839-1847 http://www.ncbi.nlm.nih.gov/pubmed/12794428

Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: A retrospective study

Zenz W, Zoehrer B, Levin M, Fanconi S, Hatzis T, Knight G, Müllner M, Faust SN
Crit Care Med 2004; 32: 1777-1780 http://www.ncbi.nlm.nih.gov/pubmed/15286558